SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.13 CNY | -0.73% |
|
+6.00% | -24.09% |
| Sales 2021 | 347M 47.93M 3.84B | Sales 2022 | 300M 41.4M 3.32B | Capitalization | 6.32B 873M 69.89B |
|---|---|---|---|---|---|
| Net income 2021 | 53M 7.31M 586M | Net income 2022 | 122M 16.84M 1.35B | EV / Sales 2021 | 28.2 x |
| Net cash position 2021 | 60.97M 8.41M 674M | Net cash position 2022 | 235M 32.38M 2.59B | EV / Sales 2022 | 20.3 x |
| P/E ratio 2021 |
191
x | P/E ratio 2022 |
51.7
x | Employees | 491 |
| Yield 2021 * |
-
| Yield 2022 |
0.58% | Free-Float | 42.29% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.73% | ||
| 1 week | +6.00% | ||
| Current month | -12.86% | ||
| 1 month | -9.06% | ||
| 3 months | -10.36% | ||
| 6 months | -27.54% | ||
| Current year | -24.09% |
1 week
7.52
8.27
1 month
7.379.62
Current year
6.0010.78
1 year
6.0011.87
3 years
6.0017.93
5 years
6.0054.03
10 years
4.2754.03
| Managers | Title | Age | Since |
|---|---|---|---|
Ben Yi Han
CEO | Chief Executive Officer | 59 | 31/07/23 |
Hua Ji
CHM | Chairman | 47 | 31/12/08 |
Qun Lin
DFI | Director of Finance/CFO | 55 | 27/12/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tian Min Liu
BRD | Director/Board Member | 63 | 24/05/21 |
Hai Ming Zhang
CHM | Chairman | 63 | - |
Yu Sheng Zhou
BRD | Director/Board Member | 69 | 13/12/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 8.13 | -0.73% | 4,502,100 |
| 25/04/24 | 8.19 | +1.36% | 3,170,400 |
| 24/04/24 | 8.08 | +1.00% | 3,577,100 |
| 23/04/24 | 8 | +2.70% | 4,670,800 |
| 22/04/24 | 7.79 | +1.56% | 4,533,700 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.
Sector
Pharmaceuticals
Calendar
29/04/2024
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -24.09% | 738M | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -2.92% | 3.12B | |
| -0.68% | 1.4B | |
| -17.27% | 1.34B | |
| -2.73% | 1.26B | |
| -28.16% | 1.2B | |
| -14.67% | 1.12B |
- Stock Market
- Equities
- 603718 Stock
